Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals
(NQ:
IONS
)
49.78
-0.46 (-0.92%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ionis Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
Next >
Why Ionis Pharmaceutical Shares Are Trading Lower Wednesday
June 07, 2023
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading lower on Wednesday after the company announced plans to offer $500 million of senior convertible notes due in 2028 in a private placement...
Via
Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
June 07, 2023
Via
Benzinga
Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79
May 24, 2023
The Relative Strength Rating for Ionis Pharmaceuticals stock moved into a new percentile Wednesday, as it got a lift from 65 to 79.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
May 04, 2023
Via
Benzinga
Recap: Ionis Pharmaceuticals Q1 Earnings
May 03, 2023
Via
Benzinga
Ionis Pharmaceuticals's Earnings Outlook
May 02, 2023
Via
Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
April 11, 2023
Via
Benzinga
Analyst Ratings for Ionis Pharmaceuticals
March 21, 2023
Via
Benzinga
Ionis Pharmaceuticals's Earnings Outlook
February 21, 2023
Via
Benzinga
Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA
April 26, 2023
The FDA approved Biogen Inc's (NASDAQ:
Via
Benzinga
What's Going On With Biogen Stock Tuesday?
April 25, 2023
Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon.
Via
Benzinga
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs
April 25, 2023
Via
Benzinga
3 Biotech Stocks to Sell Before They’re 6 Feet Under
April 24, 2023
Biotech stocks with no earnings, no cash, and no path to profit will have no chance at survival. Here's three such biotech stocks to avoid.
Via
InvestorPlace
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
April 24, 2023
Via
Benzinga
Could This Rare-Disease Drug Candidate Become a Blockbuster?
April 19, 2023
This drug candidate could be a great treatment option for patients with a potentially deadly disease.
Via
The Motley Fool
Analyst Expectations for Ionis Pharmaceuticals's Future
January 19, 2023
Via
Benzinga
The Latest Analyst Ratings for Ionis Pharmaceuticals
December 21, 2022
Via
Benzinga
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
December 13, 2022
Via
Benzinga
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
April 12, 2023
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy...
Via
Benzinga
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
March 27, 2023
Via
Benzinga
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
March 23, 2023
The companies are focusing on a small population of ALS patients with a genetic mutation.
Via
Investor's Business Daily
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
March 23, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
March 21, 2023
Via
Benzinga
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
March 16, 2023
Via
Benzinga
Analyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile'
February 21, 2023
Via
Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
February 02, 2023
The company that remains still has a large pipeline of non-migraine assets.
Via
Investor's Business Daily
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
January 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
January 04, 2023
From
Biogen Inc.
Via
GlobeNewswire
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
November 16, 2022
Neurodegenerative disorders could mean big bucks for some biotechs.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
December 21, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.